Biden Plan to Lower Drug Prices Touts Negotiation, Importation

With President Joe Biden starting to stake out his preferred strategy to lower drug prices, Washington, D.C. insiders say that policies allowing the importation of drugs from Canada and pegging Medicare drug prices to an index of international pharma costs are still under consideration by Congress. However, the experts add that both measures face long odds of making their way through the Senate.

The concept of an international drug pricing index is tied to a policy that would see Medicare negotiate the reimbursement rate of drugs with manufacturers. The international pricing index — which would likely see HHS aggregate price data from other developed countries, particularly those with Most Favored Nation trade status — would serve as the basis for the drug prices HHS negotiates with pharma. The Trump administration in December 2020 unveiled a mandatory demonstration of a most-favored-nation model that was blocked by a federal court in January. The rule was under review by the Biden administration until Aug. 6, when Biden’s HHS issued a proposed rule that would cancel the demonstration. But that draft regulation left the door open for a similar policy to be implemented later.

© 2023 MMIT
Peter Johnson

Peter Johnson

Peter has been a reporter for nearly a decade. Before joining AIS Health, Peter covered a wide variety of topics in his hometown of Seattle, where he continues to live. Peter’s work has appeared in publications including The Atlantic and The Stranger. Peter attended Colby College.

Related Posts

doctor-speaking-to-a-patient
May 25

Commercial Insurance Restrictions Complicate Biosimilar Adoption

READ MORE
shell-game
May 25

‘Shell Game’ or Rebate Maximizers? FTC Probe Reignites Debate Over GPOs

Read More
pills-in-hand
May 25

As Weight Loss Drugs’ Star Rises, Plan Sponsors, Researchers Worry About Costs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today